{
    "clinical_study": {
        "@rank": "122532", 
        "arm_group": [
            {
                "arm_group_label": "Japanese", 
                "arm_group_type": "Experimental", 
                "description": "Retigabine 300mg single-dose"
            }, 
            {
                "arm_group_label": "Caucasian", 
                "arm_group_type": "Experimental", 
                "description": "Retigabine 300mg single-dose"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, single centre, parallel group study to evaluate the safety and\n      pharmacokinetics of single oral doses of retigabine XR formulation in healthy adult Japanese\n      subjects. To compare the pharmacokinetic and safety profile, Caucasian subjects are also\n      incorporated. This study is intended to facilitate inclusion of Japanese patients in the\n      global phase III program for retigabine XR formulation."
        }, 
        "brief_title": "Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Epilepsy, Partial", 
        "condition_browse": {
            "mesh_term": [
                "Epilepsy", 
                "Epilepsies, Partial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male subject between 20 and 45 years of age inclusive, at the time of signing the\n             informed consent.\n\n          -  Japanese ancestry defined as being born in Japan, having four ethnic Japanese\n             grandparents, holding a Japanese passport or identity papers and being able to speak\n             Japanese. OR Caucasian defined as an individual having four grandparents who are all\n             descendents of the original people of Europe.\n\n          -  Healthy as determined by a responsible and experienced physician, based on a medical\n             evaluation including medical history, physical examination, laboratory tests and\n             12-lead ECG. A subject with a clinical abnormality or laboratory parameters outside\n             the reference range for the population being studied may be included only if the\n             Investigator and the GSK Medical Monitor agree that the finding is unlikely to\n             introduce additional risk factors and will not interfere with the study procedures.\n\n          -  Body weight \u2265 50 kg and BMI within the range 18.5 - 24.9 kg/m2 (inclusive).\n\n          -  Male subjects with female partners of child-bearing potential must agree to use one\n             of the contraception methods listed separately. This criterion must be followed from\n             the time of the first dose of study medication until 1 week post-last dose\n\n          -  Capable of giving written informed consent, which includes compliance with the\n             requirements and restrictions listed in the consent form.\n\n          -  AST, ALT, alkaline phosphatase and bilirubin \u2264 1.5xULN (isolated bilirubin >1.5xULN\n             is acceptable if bilirubin is fractionated and direct bilirubin <35%).\n\n          -  Single QTcB or QTcF< 450 msec; or QTc < 480 msec in subjects with Bundle Branch\n             Block.\n\n        Exclusion Criteria:\n\n          -  Subject has made a suicide attempt in the past or, in the investigator's judgment,\n             poses a significant suicide risk. Evidence of serious suicide risk may include any\n             history of suicidal behavior in the past 6 months and/or any suicidal ideation of\n             type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).\n\n          -  A positive pre-study Hepatitis B surface antigen, Hepatitis C antibody or HIV\n             antigen/antibody result within 3 months of screening\n\n          -  Current or chronic history of liver disease, or known hepatic or biliary\n             abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).\n\n          -  A positive pre-study drug/alcohol screen.\n\n          -  History of regular alcohol consumption within 6 months of the study defined as: An\n             average weekly intake of >14 drinks for males or >7 drinks for females. One drink is\n             equivalent to 12 g of alcohol: 360 ml of beer, 150 ml of table wine or 45 ml of 80\n             proof distilled spirits.\n\n          -  The subject has participated in a clinical trial and has received an investigational\n             product within the following time period prior to the first dosing day in the current\n             study: 30 days, 5 half-lives or twice the duration of the biological effect of the\n             investigational product (whichever is longer).\n\n          -  Exposure to more than four new chemical entities within 12 months prior to the first\n             dosing day.\n\n          -  Unable to refrain from the use of prescription or non-prescription drugs, including\n             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or\n             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is\n             longer) prior to the first dose of study medication, unless in the opinion of the\n             Investigator and GSK Medical Monitor the medication will not interfere with the study\n             procedures or compromise subject safety.\n\n          -  History of sensitivity to any of the study medications, or components thereof or a\n             history of drug or other allergy that, in the opinion of the investigator or GSK\n             Medical Monitor, contraindicates their participation.\n\n          -  Where participation in the study would result in donation of blood or blood products\n             in excess of 500 mL within 56 day period.\n\n          -  Unwillingness or inability to follow the procedures outlined in the protocol.\n\n          -  Subject is mentally or legally incapacitated.\n\n          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.\n\n          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco-\n             or nicotine-containing products within 6 months prior to screening.\n\n          -  Unable to refrain from consumption of red wine, seville oranges, grapefruit or\n             grapefruit juice from 7 days prior to the first dose of study medication."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691872", 
            "org_study_id": "116247"
        }, 
        "intervention": {
            "arm_group_label": [
                "Caucasian", 
                "Japanese"
            ], 
            "description": "Retigabine", 
            "intervention_name": "Retigabine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "D 23129"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 16, 2013", 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Single Centre, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the concentration-time curve from pre-dose to last time of quantifiable concentration of retigabine", 
                "measure": "AUC0-\u221e of retigabine", 
                "safety_issue": "No", 
                "time_frame": "up to 96h post dose"
            }, 
            {
                "description": "Maximum observed concentration of retigabine", 
                "measure": "Cmax of retigabine", 
                "safety_issue": "No", 
                "time_frame": "up to 96h post dose"
            }, 
            {
                "description": "Time of occurance of Cmax of retigabine", 
                "measure": "Tmax of retigabine", 
                "safety_issue": "No", 
                "time_frame": "up to 96h post dose"
            }, 
            {
                "description": "Terminal phase half-life of retigabine", 
                "measure": "t1/2 of retigabine", 
                "safety_issue": "No", 
                "time_frame": "up to 96h post dose"
            }, 
            {
                "description": "Number of participants with adverse events as a measure of safety and tolerability (evaluated by the result of Clinical safety laboratory tests, vital signs, 12-lead ECG, telemetry and clinical monitoring/observation", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 96h post dose"
            }
        ], 
        "removed_countries": {
            "country": "Japan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691872"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the concentration-time curve from pre-dose to last time of quantifiable concentration of NAMR", 
                "measure": "AUC0-\u221e of NAMR", 
                "safety_issue": "No", 
                "time_frame": "up to 96h post dose"
            }, 
            {
                "description": "Maximum observed concentration of NAMR", 
                "measure": "Cmax of NAMR", 
                "safety_issue": "No", 
                "time_frame": "up to 96h post dose"
            }, 
            {
                "description": "Time of occurance of Cmax of NAMR", 
                "measure": "Tmax of NAMR", 
                "safety_issue": "No", 
                "time_frame": "up to 96h post dose"
            }, 
            {
                "description": "Terminal phase half-life of NAMR", 
                "measure": "t1/2 of NAMR", 
                "safety_issue": "No", 
                "time_frame": "up to 96h post dose"
            }, 
            {
                "description": "Percent of retigabine and NAMR excreted in urine", 
                "measure": "fe", 
                "safety_issue": "No", 
                "time_frame": "up to 96h post dose"
            }, 
            {
                "description": "Renal clearance of retigabine and NAMR", 
                "measure": "CLr", 
                "safety_issue": "No", 
                "time_frame": "up to 96h post dose"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "July 2013", 
        "why_stopped": "Development plan of retigabine XR in Japan was readjusted."
    }
}